Viewing Study NCT06341660


Ignite Creation Date: 2025-12-25 @ 2:12 AM
Ignite Modification Date: 2026-02-26 @ 4:18 PM
Study NCT ID: NCT06341660
Status: RECRUITING
Last Update Posted: 2024-04-02
First Post: 2024-03-13
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: To Evaluate the Safety and Tolerability of Carbognilumab Combined With Chemotherapy as the First-line Treatment for Patients With KEAP1 Mutated Advanced or Postoperative Recurrent Non-small Cell Lung Cancer (NSCLC)
Sponsor: Guangzhou Institute of Respiratory Disease
Organization:

Key Dates - Follows AllAPIJSON File Order

Start Date: 2023-05-25
Start Date Type: ACTUAL
Primary Completion Date: 2025-06
Primary Completion Date Type: ESTIMATED
Completion Date: 2025-07
Completion Date Type: ESTIMATED
First Submit Date: 2024-03-13
First Submit QC Date: None
Study First Post Date: 2024-04-02
Study First Post Date Type: ACTUAL
Results First Submit Date: None
Results First Submit QC Date: None
Results First Post Date: None
Results First Post Date Type: None
Results First Post QC Date: None
Results First Post QC Date Type: None
Disp First Submit Date: None
Disp First Submit QC Date: None
Disp First Post Date: None
Disp First Post Date Type: None
Last Update Submit Date: 2024-03-26
Last Update Post Date: 2024-04-02
Last Update Post Date Type: ACTUAL